Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

The healthcare investment landscape is undergoing a revolutionary transformation, addressing the binary risk and inefficiency that have long plagued therapeutic R&D. Traditional drug development processes are slow, costly, and fraught with failure, but advances in AI are now enabling faster, more accurate drug discovery and validation. Leveraging this potential, a novel funding model has emerged, combining insurance underwriting by Lloyd’s of London and non-dilutive lending, supported by AI-driven validation technology from GATC Health. This approach reduces risk for all stakeholders, accelerates funding timelines, and maximizes the chances of success for biotech startups. With nearly 100 startups already in the pipeline, this innovative funding vehicle promises to expedite therapeutic breakthroughs, benefiting investors, companies, and most importantly, patients in need.